Altimmune Inc., a clinical stage biopharmaceutical company, is paving the way for innovative treatments for obesity and liver diseases. The Maryland-based company's primary focus is on its GLP-1/glucagon dual receptor agonist, Pemvidutide. Currently in Phase 2 trials, this candidate aims to combat obesity and non-alcoholic steatohepatitis. Altimmune is also making strides in immunotherapeutic products with its Phase 2 clinical trial candidate, HepTcell - designed for patients with chronic hepatitis B infections. Founded in 1997 under the name Vaxin Inc., Altimmune changed its name in September 2015, and its headquarters are located in Gaithersburg, Maryland.
Alternus Energy Group's ticker is ALT
The company's shares trade on the ASX stock exchange
They are based in Brisbane, Australia
There are 1-10 employees working at Alternus Energy Group
It is alternusenergy.com/about
Alternus Energy Group is in the Healthcare sector